Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in heart failure with preserved or mildly reduced ejection fraction (NYHA II–IV, LVEF ≥ 40%)
2020-000306-29Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and heart failure with mid-range ejection fraction (HFmrEF) comparing Finerenone with Placebo (2 arms). Primary endpoint: Composite of cardiovascular death and total (first and recurrent) heart failure events. Started Apr 2020; status: completed.
02
Drugs
finerenone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on 2020-000306-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000306-29.